Literature DB >> 10400610

Identification of sequences required for inhibition of oncogene-mediated transformation by pp32.

J R Brody1, S S Kadkol, M A Mahmoud, J M Rebel, G R Pasternack.   

Abstract

Oncogenic potential in prostate cancer is modulated in part by alternative use of genes of the pp32 family. This family includes the tumor suppressor pp32, expressed in normal tissue, and the pro-oncogenic genes pp32r1 and pp32r2 that are found principally in neoplastic cells. At the protein level, pp32, pp32r1, and pp32r2 are approximately 90% identical, yet they subsume opposite functions. In this study, we identify the region of pp32 associated with the ability to inhibit oncogene-mediated transformation in a rat embryo fibroblast system, an in vitro correlate of tumor-suppressive activity. Deletion and truncation analysis define a region spanning pp32 amino acids 150-174 as absolutely required for inhibition of transformed foci elicited by RAS and MYC. Comparison of pp32 with the pp32r1 sequence by moving averages of sequence identity reveals divergence over this region; pp32r2 also differs in this region through truncation after pp32 amino acid 131. The deletion experiments and the experiments of nature therefore converge to demonstrate that tumor-suppressive functions of pp32 reside in amino acids 150-174. Identification of this minimal tumor-suppressive region should help elaborate the pathways and mechanisms through which pp32 family members exert their functions.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10400610     DOI: 10.1074/jbc.274.29.20053

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  13 in total

1.  Cracking the ANP32 whips: important functions, unequal requirement, and hints at disease implications.

Authors:  Patrick T Reilly; Yun Yu; Ali Hamiche; Lishun Wang
Journal:  Bioessays       Date:  2014-08-25       Impact factor: 4.345

2.  Overexpression of the pp32r1 (ANP32C) oncogene or its functional mutant pp32r1Y140H confers enhanced resistance to FTY720 (Finguimod).

Authors:  Salma Buddaseth; Wiebke Göttmann; Rainer Blasczyk; Trevor Huyton
Journal:  Cancer Biol Ther       Date:  2013-12-12       Impact factor: 4.742

Review 3.  The Anp32 family of proteins containing leucine-rich repeats.

Authors:  Antoni Matilla; Martin Radrizzani
Journal:  Cerebellum       Date:  2005       Impact factor: 3.847

4.  Novel small molecules relieve prothymosin alpha-mediated inhibition of apoptosome formation by blocking its interaction with Apaf-1.

Authors:  Xin Qi; Lai Wang; Fenghe Du
Journal:  Biochemistry       Date:  2010-03-09       Impact factor: 3.162

5.  Analysis of the composition, assembly kinetics and activity of native Apaf-1 apoptosomes.

Authors:  Michelle M Hill; Colin Adrain; Patrick J Duriez; Emma M Creagh; Seamus J Martin
Journal:  EMBO J       Date:  2004-04-22       Impact factor: 11.598

6.  The crystal structure of the tumor suppressor protein pp32 (Anp32a): structural insights into Anp32 family of proteins.

Authors:  Trevor Huyton; Cynthia Wolberger
Journal:  Protein Sci       Date:  2007-06-13       Impact factor: 6.725

7.  PHAPI/pp32 suppresses tumorigenesis by stimulating apoptosis.

Authors:  Wei Pan; Li S da Graca; Yufang Shao; Qian Yin; Hao Wu; Xuejun Jiang
Journal:  J Biol Chem       Date:  2009-01-02       Impact factor: 5.157

Review 8.  Anp32e (Cpd1) and related protein phosphatase 2 inhibitors.

Authors:  Tomás A Santa-Coloma
Journal:  Cerebellum       Date:  2003       Impact factor: 3.847

9.  pp32 reduction induces differentiation of TSU-Pr1 cells.

Authors:  Jonathan R Brody; Shrihari S Kadkol; M Claire Hauer; Fatemeh Rajaii; Jessica Lee; Gary R Pasternack
Journal:  Am J Pathol       Date:  2004-01       Impact factor: 4.307

10.  pp32 (ANP32A) expression inhibits pancreatic cancer cell growth and induces gemcitabine resistance by disrupting HuR binding to mRNAs.

Authors:  Timothy K Williams; Christina L Costantino; Nikolai A Bildzukewicz; Nathan G Richards; David W Rittenhouse; Lisa Einstein; Joseph A Cozzitorto; Judith C Keen; Abhijit Dasgupta; Myriam Gorospe; Gregory E Gonye; Charles J Yeo; Agnieszka K Witkiewicz; Jonathan R Brody
Journal:  PLoS One       Date:  2010-11-29       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.